$5.08
3.79%
Nasdaq, Sep 12, 10:00 pm CET
ISIN
US15117F3029
Symbol
CLRB

Cellectar BioSciences, Inc. Stock price

$5.08
+0.47 10.20% 1M
-4.42 46.52% 6M
-3.89 43.37% YTD
-58.22 91.97% 1Y
-140.72 96.52% 3Y
-354.92 98.59% 5Y
-91,494.92 99.99% 10Y
-380,969,994.92 100.00% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.20 3.79%
ISIN
US15117F3029
Symbol
CLRB
Industry

Key metrics

Basic
Market capitalization
$16.2m
Enterprise Value
$5.2m
Net debt
positive
Cash
$11.0m
Shares outstanding
1.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
61.5%
Return on Equity
-284.4%
ROCE
-491.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-38.3m | -
EBIT
$-38.5m | $-25.1m
Net Income
$-29.1m | $-31.6m
Free Cash Flow
$-34.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
19.3% | -
EBIT
19.2% | 51.5%
Net Income
40.4% | 29.2%
Free Cash Flow
25.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-18.1
FCF per Share
$-19.1
Short interest
2.0%
Employees
11
Rev per Employee
$0.0
Show more

Is Cellectar BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Cellectar BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Cellectar BioSciences, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Cellectar BioSciences, Inc. forecast:

Buy
70%
Hold
30%

Financial data from Cellectar BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
17% 17%
-
- Research and Development Expense 18 18
41% 41%
-
-38 -38
19% 19%
-
- Depreciation and Amortization 0.25 0.25
7% 7%
-
EBIT (Operating Income) EBIT -39 -39
19% 19%
-
Net Profit -29 -29
40% 40%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cellectar BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectar BioSciences, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors
Neutral
GlobeNewsWire
6 days ago
Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25
Neutral
GlobeNewsWire
10 days ago
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and i...
More Cellectar BioSciences, Inc. News

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Head office United States
CEO James Caruso
Employees 11
Founded 1996
Website www.cellectar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today